Advertisement

Topics

Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

16:22 EST 9 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Robust Enrollment Continues in Phase 2 PNH Study; On Track for Data Update Around Year-end Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generat...

Other Sources for this Article

Investors:
Ra Pharmaceuticals, Inc.
Jennifer Robinson, 617-674-9873
jrobinson@rapharma.com
or
Media:
Argot Partners
Eliza Schleifstein, 917-763-8106
eliza@argotpartners.com

NEXT ARTICLE

More From BioPortfolio on "Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...